Jul 13, 2009 (GlobeNewswire via COMTEX News Network) --

           U.S. Urologist Dr. Douglas Chinn Named Clinical Instructor

                     First Ablatherm-HIFU Patient Treated At
                     Memorial Sloan-Kettering Cancer Center

LYON, France, July 13, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it has retained Douglas Chinn, MD to assist and support U.S. investigational sites in enrolling, treating, and following patients in the U.S. ENLIGHT clinical trial. Dr. Chinn will work with the current team of expert advisers to liaise between EDAP and participating physicians in the trial.

Dr. Chinn has a proven track record in bringing minimally invasive prostate cancer treatment technologies to market. He is globally recognized for his pioneering role in technical development, clinical implantation and physician training. He has published several papers and presented at medical congresses throughout the world on the topic of minimally invasive therapies. Dr. Chinn also holds several patents pertaining to minimally invasive ablative therapy.

Dr. Chinn earned his medical degree and graduated Phi Beta Kappa with a bachelor's degree in Biological Sciences at the University of Southern California (USC). He completed a surgical rotating internship, served as an Emergency Room Physician, and received urological training at LAC-USC Medical Center (LA County Hospital). After completing his residency, Dr. Chinn joined the family urology practice. He became board certified in 1985 and has been recertified twice since then.

In addition, EDAP is very pleased to announce that Memorial Sloan-Kettering Cancer Center in New York City has successfully completed its first Ablatherm-HIFU treatment at the center. The procedure was performed by Dr. James A. Eastham, MD, Chief Urology Service and proctored by Dr. William Orovan from Toronto, Canada.

Dr. Chinn commented, "I am very excited to assist with the ENLIGHT clinical trial and work with EDAP to introduce Ablatherm-HIFU therapy as a minimally invasive treatment option to the U.S. market. The HIFU technology represents a major breakthrough for treating patients with prostate cancer. I plan to leverage my experience in developing and conducting training programs for novel prostate cancer therapies and to work with many of the top prostate cancer institutions, including Memorial Sloan-Kettering that is currently participating in the trial."

Dr. John Rewcastle, Medical Director of EDAP, added, "I am pleased to welcome Dr. Chinn as a valuable member on our U.S. clinical team. He will work closely with physicians at investigational sites as part of EDAP's continuing medical education program. Dr. Chinn has more in depth Ablatherm experience than any physician in the United States, having worked with Ablatherm experts in Regensburg, Germany and Toronto, Canada. He has treated and followed a large number of patients treated with the Ablatherm, and his experience and prior success in training and working with physicians to adopt technologies will positively impact our patient accrual efforts."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS SA

EDAP TMS SA
          Investor Relations / Legal Affairs
          Blandine Confort
          +33 4 72 15 31 72
          bconfort@edap-tms.com

          The Ruth Group
          Investors:
          R.J. Pellegrino
            646-536-7009
            rpellegrino@theruthgroup.com
          Nick Laudico
            646-536-7030
            nlaudico@theruthgroup.com

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX